Speich B et al: Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: A four-arm, randomised controlled trial. Lancet Infect Dis 2015;15:277.
Speich B et al: Oxantel pamoate-albendazole for Trichuris trichiura infection. N Engl J Med 2014;370:610.
Steinmann P et al: Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: A randomized controlled trial. PLoS One 2011;6:e25003.
Supali T et al: Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008;46:1385.
Tamarozzi F et al: Acceptance of standardized ultrasound classification, use of albendazole, and long-term follow-up in clinical management of cystic echinococcosis: A systematic review. Curr Opin Infect Dis 2014;27:425.
Taylor MJ et al: Lymphatic filariasis and onchocerciasis. Lancet 2010;376:1175.
Zwang J, Olliaro PL: Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis-a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl Trop Dis 2014;8:e3286.
The presentation is highly suggestive of cystic hydatid disease (infection with Echinococcus granulosus), which is transmitted by eggs from the feces of dogs in contact with livestock. Other causes of liver fluid collections include ame-bic and pyogenic abscesses, but these are usually not cystic in appearance. For echinococcosis, a typical cystic lesion and positive serology support the diagnosis, and treatment generally entails albendazole in conjunction with cautious surgery or percutaneous aspiration. One approach entails treatment with albendazole followed by aspiration to con-firm the diagnosis and, if it is confirmed, to remove most of the infecting worms.
Edward Chu, MD are the possible benefits of adjuvant chemotherapy? The patient receives a combination of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) as adjuvant therapy. One week after receiving the first cycle of therapy, he experiences significant toxicity in the form of myelosup-pression, diarrhea, and altered mental status. What is the most likely explanation for this increased toxicity? Is there any role for genetic testing to determine the etiology of the increased toxicity? A 55-year-old man presents with increasing fatigue, 15-pound weight loss, and a microcytic anemia. Colonoscopy identifies a mass in the ascending colon, and biopsy specimens reveal well-differentiated colorectal cancer (CRC). He undergoes surgical resection and is found to have high-risk stage III CRC with five positive lymph nodes. After surgery, he feels entirely well with no symptoms. Of note, he has no other illnesses. What is this patient’s overall prognosis? Based on his prognosis, what